Equities research analysts forecast that Chimerix Inc (NASDAQ:CMRX) will post ($0.36) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Chimerix’s earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.38). Chimerix reported earnings of ($0.42) per share in the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The business is expected to report its next quarterly earnings results on Monday, May 6th.
According to Zacks, analysts expect that Chimerix will report full-year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.25). For the next year, analysts expect that the company will post earnings of ($1.23) per share, with EPS estimates ranging from ($1.33) to ($1.05). Zacks’ EPS averages are an average based on a survey of research firms that cover Chimerix.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.07. Chimerix had a negative return on equity of 35.97% and a negative net margin of 951.77%. The firm had revenue of $4.86 million during the quarter, compared to the consensus estimate of $0.85 million.
NASDAQ:CMRX traded up $0.02 during trading hours on Friday, reaching $2.56. 6,651 shares of the stock were exchanged, compared to its average volume of 480,285. Chimerix has a twelve month low of $1.74 and a twelve month high of $5.04. The company has a market cap of $129.29 million, a P/E ratio of -1.77 and a beta of 1.35.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of Chimerix by 6.2% in the 3rd quarter. BlackRock Inc. now owns 3,711,445 shares of the biopharmaceutical company’s stock valued at $14,439,000 after buying an additional 215,268 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Chimerix by 2.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,612,871 shares of the biopharmaceutical company’s stock valued at $6,715,000 after buying an additional 56,347 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Chimerix by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,115,044 shares of the biopharmaceutical company’s stock valued at $8,228,000 after buying an additional 126,847 shares during the last quarter. Vanguard Group Inc boosted its holdings in shares of Chimerix by 6.4% in the 3rd quarter. Vanguard Group Inc now owns 2,115,044 shares of the biopharmaceutical company’s stock valued at $8,228,000 after buying an additional 126,847 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in shares of Chimerix by 28.8% in the 3rd quarter. Morgan Stanley now owns 2,041,150 shares of the biopharmaceutical company’s stock valued at $7,940,000 after buying an additional 456,290 shares during the last quarter. 73.06% of the stock is owned by institutional investors.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Article: Why is total return important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.